Financials, Europe debt auctions lift Wall Street (Reuters)

NEW YORK (Reuters) ? U.S. stocks rose early Thursday, putting the S&P on track for its third straight advance after Bank of America and Morgan Stanley earnings lifted financials and strong demand at European bond auctions eased euro zone debt concerns.

Bank of America Corp (BAC.N) climbed 4.4 percent to $7.10 as the top boost to the benchmark S&P. The bank reported a fourth-quarter profit, reversing a year-earlier loss, boosted by one-time items and lower expenses for bad loans.

Fellow financial Morgan Stanley (MS.N) jumped 4.6 percent to $18.15 after the Wall Street bank posted a quarterly loss but still managed to top analysts’ expectations.

“It’s the reaction to Morgan Stanley and Bank of America, to their earnings reports. People were expecting absolute disaster, it wasn’t an absolute disaster and people looked at those numbers and walked away thinking both those companies wouldn’t need to raise more capital,” said Stephen Massocca, managing director at Wedbush Morgan in San Francisco.

Financial shares have rallied since the start of the year. The S&P financial index (.GSPF) is up 8 percent for 2012, helping to push the S&P 500 up more than 4 percent. The financial index was up 0.8 percent for the session.

But gains were muted as investors showed some cautiousness after a rally that has sent the S&P 500 to levels not seen since late July.

“We are due for at least some consolidation. We had a pretty good rally here and we broke out above the old October high so it’s only natural that we get some backing and filling here,” said Massocca.

The Dow Jones industrial average (.DJI) rose 28.91 points, or 0.23 percent, at 12,607.86. The Standard & Poor’s 500 Index (.SPX) was up 5.33 points, or 0.41 percent, at 1,313.37. The Nasdaq Composite Index (.IXIC) put on 18.74 points, or 0.68 percent, at 2,788.45.

In a sign that investor nervousness over the euro zone’s debt crisis was easing, Spain and France both drew strong demand at government debt auctions.

The Nasdaq got a boost from eBay Inc (EBAY.O), which reported better-than-expected results after the close on Wednesday. The stock was up 4.8 percent to $31.80.

Transportation stocks moved higher after Union Pacific Corp (UNP.N) reported higher quarterly profit and revenue that beat estimates. Union Pacific was up 3.8 percent to $114.02, while the Dow Jones Transportation Average (.DJT) gained 1.4 percent.

New data generally supported the view the U.S. economy continued to improve at a moderate pace. Weekly jobless claims dropped to a near four-year low, consumer prices showed inflation remained in check, while factory activity in the Mid-Atlantic region edged up, but less than expected.

However, housing starts dipped, suggesting the sector was still a ways from strengthening.

After the close, quarterly reports are due from technology bellwethers Google Inc (GOOG.O), International Business Machines Corp (IBM.N), Intel Corp (INTC.O) as well as Microsoft Corp (MSFT.O).

(Reporting By Chuck Mikolajczak; editing by Jeffrey Benkoe)

Source: http://us.rd.yahoo.com/dailynews/rss/eurobiz/*http%3A//news.yahoo.com/s/nm/20120119/bs_nm/us_markets_stocks

occupy chicago ron white ron white alcs alcs miguel cabrera pay it forward

Somersaulting fly captured in slow-mo wins award

Sandrine Ceurstemont, editor, New Scientist TV

Think flies aren’t acrobatic? In this video, watch a fly perform an aerial somersault in slow motion, a move seldom observed in real time due to its speed. Captured by biologists Michael Dickinson from the University of Washington and Gwyneth Card from the Howard Hughes Medical Institute, it’s an escape manoeuvre performed when a fly is taken by surprise, allowing it to regain control during the tumble.

The short film is one of the winners in a competition organised by the Flight Artists group at Wageningen University in the Netherlands. The team taught amateur filmmakers how to use high-speed cameras to capture flying animals, or plant seeds, and selected the best results.

Dickinson and Card typically study fruit flies in flight, for example to find out more about wing dynamics and how the brain translates decisions into motion.

If you enjoyed this video, check out a bald eagle in flight and a swallow feeding its young, videos captured by the Flight Artists team last year.

Subscribe to New Scientist Magazine

Source: http://feeds.newscientist.com/c/749/f/10897/s/1bf5bd41/l/0L0Snewscientist0N0Cblogs0Cnstv0C20A120C0A10Csomersaulting0Efly0Ecaptured0Ein0Eslow0Emo0Ewins0Eaward0Bhtml0DDCMP0FOTC0Erss0Gnsref0Fonline0Enews/story01.htm

occupy wallstreet occupy wallstreet tony bennett pumpkins pumpkins occupy wall st occupy wall st

Experimental Drug Might Help Some a Bit With Colon Cancer (HealthDay)

TUESDAY, Jan. 17 (HealthDay News) — The experimental cancer drug regorafenib appears to extend survival slightly in patients with metastatic colorectal cancer, a new trial indicates.

Regorafenib is a so-called multikinase inhibitor, which targets several of the ways cancer develops and grows, researchers said.

“The drug was tested on patients with metastatic colorectal cancer who had progressed after standard therapies, meaning they had no treatment options available,” lead researcher Dr. Axel Grothey, a professor of oncology at the Mayo Clinic, said during a noon press conference at the Gastrointestinal Cancers Symposium in San Francisco on Tuesday.

The drug is designed to stop tumor progression, both by preventing cancer cells from growing and by preventing these cells from developing the blood vessels needed to keep them alive, the researchers explained.

In the trial, more than 700 patients with metastatic colon cancer were randomly selected to receive regorafenib or placebo.

In addition, all patients received care to treat symptoms, but not to change the course of the disease, the researchers noted.

Treatment included antibiotics to fight infections, painkillers and corticosteroids.

The investigators found that patients taking regorafenib survived an average of 6.4 months, compared with five months for those receiving a placebo — an increase in survival of 29 percent.

In addition, 44 percent of the patients taking regorafenib responded to the drug or had their cancer slowed, compared with 15 percent of the patients receiving placebo, they reported.

Based on these findings, the trial was stopped in October so that all patients could be offered the drug.

The trial was funded by the maker of regorafenib, Bayer HealthCare Pharmaceuticals.

“The drug helped patients live longer,” said Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society. “But you have to keep in mind that these patients had advanced disease.”

And, the gains were modest, he added. “Patients who got the drug lived about one month longer. Unfortunately, the difference between the groups in the time it took for the disease to get worse was small — about six days,” he said.

Lichtenfeld thinks that using the drug earlier in treatment might have more impact. “But not every drug, when moved earlier in the course of the disease, is necessarily proven to be effective,” he cautioned.

Grothey noted regorafenib is being tested in a phase 2 trial in patients with earlier stage colorectal cancer, in hopes that the results will be even more dramatic.

Research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed medical journal.

More information

For more on colon cancer, visit the American Cancer Society.

Source: http://us.rd.yahoo.com/dailynews/rss/cancer/*http%3A//news.yahoo.com/s/hsn/20120119/hl_hsn/experimentaldrugmighthelpsomeabitwithcoloncancer

scrimshaw jacoby ellsbury jacoby ellsbury facebook charging act scores the good wife facebook changes

Apple co-founder praises Android over Apple?s iPhone

You are here: Home / News / Apple co-founder praises Android over Apple?s iPhone

Posted by Josh on January 17, 2012 ? Leave a Comment?

Apple is a company that is well known for having Steve Job as the face of the company for many years, however, the company was actually co-founded by Steve Jobs and a man named Steve Wozniak. Now, Steve Wozniak has spoken out about the iPhone and has actually said that he thinks that Android have stepped ahead of the iPhone in many ways.

Steve Wozniak explained that he has an iPhone as his primary phone and that it is a beautiful device, but that he also has an Android device and that he wishes that the iPhone would do some of the things that this phone does. He explained that he liked the GPS system better on the Android phones and that he also found the Siri function to not be as good as it should be on the iPhone 4S. Steve also said that he thinks that Android have in some ways overtaken Apple.

Steve explained that he would love to see Apple incorporate some of the features of the Android phone and that he would mainly recommend the iPhone to anyone who is already in a Mac world as it is compatible.

Related posts:

  1. Apple developer brings Siri to the iPhone 3GS Siri is the latest craze in the world of Apple…
  2. Android Phone users consider switching to iPhone Android and Apple are companies that are currently at war…
  3. Apple iPhone 4S expected to break sales records Apple?s iPhone 4 and the 3GS devices have all been…
  4. Apple iPhone vs. Android vs. Windows; which should you choose There are so many Smartphone?s on the market these days…
  5. Apple iPhone 4S Christmas Ad Most Effective of the Season Apple?s iPhone 4S device is the latest iPhone to be…

Related posts brought to you by Yet Another Related Posts Plugin.